MKC-1
CAS No. 125313-92-0
MKC-1( —— )
Catalog No. M28925 CAS No. 125313-92-0
MKC-1 is an orally bioavailable, small-molecule, bisindolylmaleimide cell cycle inhibitor with potential antineoplastic activity. MKC-1 and its metabolites inhibit tubulin polymerization, blocking the formation of the mitotic spindle.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 129 | In Stock |
|
| 5MG | 121 | In Stock |
|
| 10MG | 178 | In Stock |
|
| 25MG | 309 | In Stock |
|
| 50MG | 436 | In Stock |
|
| 100MG | 608 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMKC-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionMKC-1 is an orally bioavailable, small-molecule, bisindolylmaleimide cell cycle inhibitor with potential antineoplastic activity. MKC-1 and its metabolites inhibit tubulin polymerization, blocking the formation of the mitotic spindle.
-
DescriptionMKC-1 is an orally bioavailable, small-molecule, bisindolylmaleimide cell cycle inhibitor with potential antineoplastic activity. MKC-1 and its metabolites inhibit tubulin polymerization, blocking the formation of the mitotic spindle.
-
In Vitro——
-
In VivoMKC-1 (200 mg/kg, orally, daily) significantly increased the median survival time (MST) of mice bearing Caki-1 renal cell xenograft tumors.
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number125313-92-0
-
Formula Weight400.394
-
Molecular FormulaC22H16N4O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 50 mg/mL (124.88 mM)
-
SMILESCn1cc(C2=C(C(=O)NC2=O)c2cn(C)c3cc(ccc23)[N+]([O-])=O)c2ccccc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Hyland EE, et al. Unified Access to Pyrimidines and Quinazolines Enabled by N-N Cleaving Carbon Atom Insertion. J Am Chem Soc. 2022 Oct 26;144(42):19258-19264.
molnova catalog
related products
-
PCC0208017
PCC0208017 is an inhibitor of MARK3 and MARK4 with IC50s of 1.8 and 2.01 nM. PCC0208017 disrupts microtubule dynamics and displays potent antitumor activity.
-
LDCA
LDCA is a double-hit metabolic regulator that exhibits potent anti-proliferative activity. lDCA competitively inhibits LDH-A enzyme activity, alters mitochondrial hyperpolarization and simultaneously subverts apoptosis.
-
BFC1108
BFC1108 targets Bcl-2 and converts it to a pro-apoptotic protein, inhibits the growth of triple-negative breast cancer xenografts with high Bcl-2 expression, inhibits breast cancer lung metastasis, and induces apoptosis of Bcl-2-expressing cancer cells.
Cart
sales@molnova.com